Article
Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Journal of oncology practice - 1 Apr 2016
Mantripragada Kalyan C, Olszewski Adam J, Schumacher Andrew, Perez Kimberly, Birnbaum Ariel, Reagan John L, Mega Anthony, Khurshid Humera, Bartley Carolyn, Lombardo Alise, Rossiter Rachael, Papa Alessandro, Bakalarski Pamela, Safran Howard
Abstract excerpt
PURPOSE: Successful clinical trial accrual targeting uncommon genomic alterations will require broad national participation from both National Cancer Institute (NCI)-designated comprehensive cancer centers and community cancer programs. This report describes the initial experience with clinical trial accrual after next-generation sequencing (NGS) from three affiliated non-NCI-designated cancer programs. MATERIALS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.